Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation-Reference-Cited by-同舟云学术

Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation

Published:2015-11-07 Issue:3 Volume:34 Page:285-301
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Wagner Monika,Khoury Hanane,Willet Jacob,Rindress Donna,Goetghebeur Mireille

Funder

This study was made possible by a research grant from Genzyme, Cambridge USA

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-015-0340-5.pdf

Reference96 articles.

1. EURORDIS. Rare diseases: understanding this public health priority. EURORDIS. 2005. Available at: http://www.eurordis.org/publication/rare-diseases-understanding-public-health-priority . Accessed 21 Oct 2013.

2. Barrera LA, Galindo GC. Ethical aspects on rare diseases. Adv Exp Med Biol. 2010;686:493–511.

3. Kole A, Faurisson F. Rare diseases social epidemiology: analysis of inequalities. Adv Exp Med Biol. 2010;686:223–50.

4. Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab. 2006;88(3):208–15.

5. Gomez-Rubio V, Lopez-Quilez A. Statistical methods for the geographical analysis of rare diseases. Adv Exp Med Biol. 2010;686:151–71.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Societal Preferences in Health Technology Assessments for Rare Diseases and Orphan Drugs: A Systematic Literature Review of New Analytic Approaches;Value in Health Regional Issues;2024-11

2. Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks;Value in Health;2024-09

3. The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD);Orphanet Journal of Rare Diseases;2024-08-23

4. Validation, adaptation and application of a multi‐criteria decision analysis‐based framework for chemotherapeutic agents in Egypt;Journal of Multi-Criteria Decision Analysis;2024-05

5. Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions;Journal of Comparative Effectiveness Research;2024-02